What biochemical tests and timing should be used to assess remission after surgical treatment for Cushing's disease?

Assessing Remission After Surgical Treatment for Cushing's Disease

Measure morning serum cortisol within 48 hours postoperatively, with a level <50 nmol/L (<1.8 μg/dL) indicating immediate biochemical remission, and perform an overnight 2 mg low-dose dexamethasone suppression test (LDDST) on postoperative day 5 for cases with borderline or elevated cortisol to enhance prediction of long-term remission. 1

Immediate Postoperative Assessment (First 48 Hours)

The most critical early marker is the morning serum cortisol nadir within 48 hours after transsphenoidal surgery:

• Cortisol <50 nmol/L (1.8 μg/dL): Indicates immediate postoperative biochemical remission (IPBR) with 99.4% remission rate at first follow-up 1
• Cortisol ≤138 nmol/L (5 μg/dL): Associated with 100% specificity and positive predictive value for remission 2
• Cortisol >585 nmol/L (21 μg/dL): Indicates high risk of treatment failure 3

The Endocrine Society guidelines recommend an individualized approach based on whether postoperative cortisol categorizes the patient as hypocortisolemic, eucortisolemic, or hypercortisolemic 4.

Enhanced Assessment at Day 5

For patients without immediate biochemical remission (morning cortisol >50 nmol/L), perform an overnight 2 mg LDDST on postoperative day 5 1:

• Complete suppression (<50 nmol/L): 98.5% remission rate at first follow-up and only 6.8% five-year recurrence risk
• Failure to suppress: 71.1% five-year recurrence risk
• This test adds significant diagnostic value beyond morning cortisol alone, particularly for borderline cases

Important caveat: The LDDST should be performed selectively in cases without IPBR rather than universally, as it provides the most value when morning cortisol is equivocal 1.

Assessment at 10-14 Days

Measure morning cortisol again at 10-12 days postoperatively (before that day's glucocorticoid replacement dose if applicable):

• Cortisol ≤157 nmol/L (5.7 μg/dL): 91% sensitivity, 100% specificity for remission 2
• Cortisol <35 nmol/L (1.3 μg/dL): Suggests favorable long-term outcome 5

The Endocrine Society recommends measuring late-night salivary or serum cortisol in patients with eucortisolism after surgery 4.

Assessment at 6-12 Weeks

Cortisol levels at 6-12 weeks provide better discrimination of continuing remission than earlier measurements 5:

• Levels are typically lower than those obtained within 2 weeks of surgery
• Cortisol <35 nmol/L (1.3 μg/dL) at this timepoint suggests favorable long-term outcome
• All four patients who relapsed in one series had cortisol >52 nmol/L at 6-12 weeks 5

Complementary Markers

ACTH levels at 24 hours postoperatively can provide additional predictive value 3:

• ACTH ≤7.55 pmol/L (34 pg/mL): 80% sensitivity, 97.4% specificity for remission
• Combine with cortisol for enhanced accuracy

Histopathological confirmation of adenoma removal is also predictive—87% of patients in remission had identified adenoma vs. only 20% of treatment failures 3.

Long-Term Monitoring for Recurrence

The Endocrine Society recommends using screening tests for hypercortisolism to assess for recurrence in patients with ACTH-dependent Cushing's syndrome 4:

• Assess HPA axis recovery every 3 months with morning cortisol (before glucocorticoid dose)
• When morning cortisol reaches ≥200 nmol/L (7.4 μg/dL), perform ACTH stimulation test 4
• HPA axis recovery confirmed when baseline or stimulated cortisol is ≥500 nmol/L (18 μg/dL) 4
• Continue monitoring with 24-hour urinary free cortisol, late-night salivary cortisol, or overnight 1 mg dexamethasone suppression test at regular intervals

Algorithmic Approach

1. Day 1-2: Morning serum cortisol

   • <50 nmol/L → IPBR confirmed, start glucocorticoid replacement

   • 585 nmol/L → Treatment failure likely, consider additional therapy

   • 50-585 nmol/L → Proceed to step 2

2. Day 5: Overnight 2 mg LDDST (for non-IPBR cases)

   • Suppression <50 nmol/L → Remission likely
   • No suppression → High recurrence risk, close monitoring

3. Day 10-14: Repeat morning cortisol

   • <157 nmol/L → Remission confirmed

   • 157 nmol/L → Consider additional treatment

4. 6-12 weeks: Morning cortisol

   • <35 nmol/L → Excellent long-term prognosis

   • 52 nmol/L → Increased relapse risk

5. Every 3 months: Monitor HPA axis recovery until cortisol ≥200 nmol/L, then perform stimulation testing

Critical pitfall: Cortisol levels in the immediate postoperative period should be interpreted cautiously if between 50-585 nmol/L. The decision to immediately re-explore should be individualized based on surgical findings, histopathology, and serial cortisol trends 6.